Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company save search
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
Published: 2021-12-02 (Crawled : 11:00) - globenewswire.com
BOLT | $1.2002 8.13% 6.72% 150K
|
|
| O: 3.22%
H: 8.6%
C: 6.35%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 2.17%
H: 0.0%
C: 0.0%
trial therapeutics phase 1 iot
CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
Published: 2021-12-02 (Crawled : 01:00) - prnewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 2.17%
H: 0.0%
C: 0.0%
deadline
Global Lymphoma Treatment Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Published: 2021-12-01 (Crawled : 19:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -1.01%
H: 0.65%
C: 0.21%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 2.17%
H: 0.0%
C: 0.0%
ABT | News | $106.89 -0.65% 0.07% 4.2M
|
Health Technology
|
| O: -0.36%
H: 2.82%
C: 1.65%
treatment growth
Parthenon Therapeutics Appoints Tamas Oravecz, Ph.D., as Chief Scientific Officer
Published: 2021-12-01 (Crawled : 13:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -1.03%
H: 2.04%
C: 0.76%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
therapeutics vtama
Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -3.29%
H: 0.0%
C: 0.0%
therapeutics presentation cancer breast cancer symposium
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: -1.18%
H: 1.16%
C: 0.49%
psoriasis food treatment europe application drug plague
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2021-11-23 (Crawled : 12:30) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.0%
H: 0.0%
C: 0.0%
europe approval ulcerative colitis
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
Published: 2021-11-19 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.15%
H: 0.49%
C: -2.2%
pdufa mavacamten
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
Published: 2021-11-19 (Crawled : 04:00) - prnewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.15%
H: 0.49%
C: -2.2%
deadline
Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
Published: 2021-11-18 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.81%
H: 0.42%
C: -0.69%
biotech iot
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
Published: 2021-11-15 (Crawled : 17:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 1.63%
H: 0.43%
C: -0.3%
phase 2
Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at The Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Published: 2021-11-13 (Crawled : 16:20) - prnewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
| Email alert
Add to watchlist
INTS | $3.99 -1.48% -2.92% 4.1K
|
| Email alert
Add to watchlist
immunotherapy solid tumors therapy results cancer
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -10.51%
H: 0.0%
C: 0.0%
phase 1 results antibody
Worldwide Active Pharmaceutical Ingredient Industry to 2030 - Growing Importance of Generics is Driving the Market
Published: 2021-11-12 (Crawled : 21:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
| Email alert
Add to watchlist
TEVA | $13.01 -0.31% 7.1M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
| Email alert
Add to watchlist
growing
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting
Published: 2021-11-12 (Crawled : 13:00) - prnewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
results
Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
Published: 2021-11-11 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 12.1%
H: 0.0%
C: 0.0%
expansion collaboration announces collaboration
TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-11-10 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.27%
H: 1.09%
C: 0.15%
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: -2.12%
H: 6.51%
C: 0.72%
financial results results
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
Published: 2021-11-10 (Crawled : 11:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.27%
H: 1.09%
C: 0.15%
collaboration designation
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
Published: 2021-11-09 (Crawled : 13:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
BHVN | News 0 d | $38.72 -2.25% 0.78% 760K
|
Health Technology
|
| O: -20.3%
H: 0.0%
C: 0.0%
commercialization collaboration
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
Published: 2021-11-08 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
heart cardiovascular cardio
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.